Takeaway
- This meta-analysis suggests that statin use may confer moderate mortality benefit in people living with HIV.
Why this matters
- Dyslipidaemias are the most common cardiometabolic disorders that affect people with HIV.
- Although studies of statins in HIV have evaluated subclinical cardiovascular disease (CVD), none has evaluated associations between statin use and hard CVD endpoints.
Study design
- Systematic review and meta-analysis of 7 studies including 35,708 participants with HIV from inception up to April 2018.
- Funding: None disclosed.
Key results
- Overall, percentage of participants receiving statin therapy was between 8% and 35% and the percentage of participants with hypertension was between 14% and 35%.
- 33% reduced risk was seen among patients receiving statin therapy (HR, 0.67; 95% CI, 0.39-0.96).
- In the sensitivity analyses after removing the lower quality studies, the pooled HR from the 2 weighting schemes were 0.82 (95% CI, 0.49-1.35) and 0.76 (95% CI, 0.50-1.13), respectively, for mortality risk after statin use.
- Mortality rate due to cardiovascular disease was reported by 2 studies (pooled HR, 0.69; 95% CI, 0.37-1.62).
Limitations
- Observational studies were included.
- Risk for bias.
References
References
